Loading organizations...
Sabby Management, LLC operates as an investment firm providing active management for private investment funds. The firm specializes in US public equities, frequently focusing on nano and micro-cap companies. Employing diverse strategies, Sabby Management applies discretionary oversight to capital allocation, including via sector-specific vehicles like the Sabby Healthcare Master Fund, to capitalize on opportunities.
Hal D. Mintz established Sabby Management in 2011, serving as its managing partner. Mintz's founding insight centered on the potential for specialized, active management to exploit inefficiencies within particular equity market segments. His expertise guides the firm's strategic focus, aiming to create value by engaging with companies often overlooked by broader mandates.
The firm primarily serves institutional clients seeking specialized capital solutions. Sabby Management's vision is to generate performance through rigorous, adaptive investment strategies and disciplined capital deployment. They optimize outcomes by strategically participating in dynamic public securities markets.
Sabby Management has 2 tracked investments across 2 companies. The latest tracked deal is $41.0M Series C in Xeris Biopharma in January 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 8, 2016 | Xeris Biopharma | $41.0M Series C | ROB Faulkner | Deerfield Management, The Mcnair Group |
| Jun 1, 2015 | Cogent Biosciences | $65.0M Series B | Liam Ratcliffe | Access Biotechnology, Atlas Venture, Brandon Capital Partners, Josh Resnick, Brace Pharma Capital, Cowen Private Investments, F Prime Capital, Jennison Associates, Novo Holdings, Sanofi Ventures, Seattle Genetics, Sectoral Asset Management, Wellington Management |
